Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin a by human liver in vitro

Therapeutic Drug Monitoring

Volumn 19, Issue 4, 1997, Pages 436-445

  Omar, Ghada ^a   Whiting, Paul H ^a   Hawksworth, Gabrielle M ^b   Humphrey, Michael J ^c   Burke, M Danny ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Antifungal agents; Cyclosporin A; Drug interactions; Drug metabolism; Inhibitors; P450

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450; DRUG METABOLITE; FLUCONAZOLE; KETOCONAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER MICROSOME METABOLISM; LIVER TRANSPLANTATION; MALE; METABOLIC INHIBITION; PRIORITY JOURNAL;

EID: 0031423883     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199708000-00013     Document Type: Article

References (55)

1. Faulds D, Goa KL, Benfield P. Cyclosporin - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953-1040.
2. Burke MD, Macintyre F, Cameron D, Whiting PH. Cyclosporin A metabolism and drug interactions. In: Thomson AW, ed., Cyclosporin - mode of action and clinical applications. Kluwer: Dordrecht; 1989;267-302.
3. Watkins PB. The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol 1990;23:1301-1311.
4. Lokiec F, Poirier O, Gluckman E, Devergie A, Arcese W. Pharmacokinetic study of cyclosporine A: preliminary results. In: Bone Marrow Transplantation in Europe. Vol 2. Proceedings of the Fifth European Symposium on Bone Marrow Transplantation. Amsterdam: Excerpta Medica. 1981:160-164.
5. Ferguson RM, Sutherland DER, Simmons RL, Najarian JS. Ketoconazole, cyclosporin metabolism and renal transplantation. Lancet 1982;ii:882-883.
6. Dieperink H, Moller J. Ketoconazole and cyclosporine. Lancet 1982;ii:1217.
7. Morgenstern GR, Powles R, Robinson B, McElwain TJ. Cyclosporin interaction with ketoconazole and melphalan. Lancet 1982;ii:1342.
8. Shephard JH, Canafax DM, Simmons RL, Najarian JS. Cyclosporine-ketoconazole: a potentially dangerous drug-drug interaction. Clin Pharmacol 1986;5:468.
9. Schroeder TJ, Melvin DB, Clardy CW, et al. Use of cyclosporine and ketoconazole without nephrotoxicity in two heart transplant recipients. J Heart Transplant 1987;6:84-89.
10. First MR, Schroeder TJ, Weiskittel P, Myre SA, Alexander JW, Pesce AJ. Concomitant administration of cyclosporin and ketoconazole in renal patients. Lancet 1989;ii:1198-1201.
11. Butman SM, Wild J, Fagan T, Mackie M, Finley P, Copeland JG. The first year of cyclosporine and concomitant ketoconazole after cardiac transplantation. J Heart Transplant 1989;8:95.
12. Girardet RE, Melo JC, Fox MS, Whalen C, Lusk R, Masri ZH, Lansing AM. Concomitant administration of cyclosporine and ketoconazole for three and a half years in one heart transplant recipient. Transplantation 1989;48:887-890.
13. First MR, Schroeder TJ, Alexander JW, Stephens GW, Weiskittel P, Myre SA, Pesce AJ. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991;51:365-370.
14. Diaz Couselo FA, Porato F, Turin M, Etchegoyen FP, Diez RA. Interactions of cyclosporine in renal transplant recipients. Medicina 1992;52:296-302.
15. Meredith CG, Maldonado AL, Speeg KV. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab Disp 1985;13:156-162.
16. Brown MW, Maldonado AL, Meredith CG, Speeg KV. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther 1985;37:290-297.
17. Back DJ, Tija JF, Karbwang, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988;26:23-29.
18. Back DJ, Stevenson P, Tija JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989;28:166-170.
19. Burke MD, Omar G, Thomson AW, Whiting PH. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. Transplantation 1990;50:901-902.
20. Henricsson S, Lindholm A, Aravoglou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol. Toxicol. 1990;66:49-52.
21. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB 1992;6:752-758.
22. Daneshmend TK. Ketoconazole-cyclosporin interaction. Lancet 1982;ii:1342-1343.
23. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988;32:1-8.
24. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12:5318-5326.
25. Back DJ, Tija JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-626.
26. Houston JB, Humphrey MJ, Matthew DE, Tarbit MH. Comparison of two azole antifungal drugs, ketoconazole and fluconazole, as modifiers of rat hepatic monooxygenase activity. Biochem Pharmacol 1988;37:401-408.
27. Conti DJ, Tolkoff-Rubin NE, Baker GP, et al. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation 1989;48:692-695.
28. Kruger HU, Schuler U, Zimmerrnan R, Ehninger G. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989;24:781-786.
29. Rieth H, Sauebrey N. Interaction studies with fluconazole, a new triazole antifungal drug. Wien Med. Wochenschr 1989;139:370-374.
30. Sugar AM, Saunders C, Idelson BA, Bernard DB. Interaction of fluconazole and cyclosporine. Ann Intern Med 1989;110:844.
31. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991;51:1014-1018.
32. Howitt KM, Oziemski MA. Phenytoin toxicity induced by fluconazole. Med J Austral 1989;151:603-604.
33. Kowalsky SF. Drug interactions with fluconazole. Pharmacother 1990;10:170S-173S.
34. La Delfa I, Xia Y, Blaschke TF. Dose-dependent inhibition of cyclosporine metabolism in mice by fluconazole. Can J Physiol Pharmacol 1990;68:89-93.
35. Weaver RJ RJ, Dickins M, Burke MD: Cytochrome P450 2C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver. Biochem Pharmacol 1993;46:1183-1197.
36. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 11951;93:265-275.
37. Christians U, Strohmeyer S, Kownatzki R, et al. Investigation on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile - isolation of 12 new metabolites. Xenobiotica 1991;211:185-1198.
38. Yatscoff RW, Rosano TG, Bowers LD. The clinical significance of cyclosporine metabolites. Clin. Biochem 1991;24:23-35.
39. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-45OIII gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-635.
40. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P. Metabolism of cyclosporin A (IV) purification and identification of the rifampicin inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P45OIIIA gene subfamily. Drug Metab Disp 1989;17:197-207.
41. Shaw PM, Barnes TS, Cameron D, et al. Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochem J 1989;263:653-663.
42. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P. Cyclosporin A drug interactions-screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Disp 1990;18:595-606.
43. Shaw TB, Tarbit MH, Troke PF. Cytochrome P-450 mediated sterol synthesis and metabolism: differences in sensitivity to fluconazole and other azoles. In: Fromtling RA. ed. Recent trends in the discovery, development and evaluation of antifungal agents. SA: Prous Science Publishers. 1987:125-139.
44. Dixon M, Webb EC. Enzymes. London: Longmans, Greenand Co Ltd, London, 1964.
45. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982;23:1-36.
46. Dismukes WE, Cloud G, Bowles C, et al. Treatment of blastomycosis and histoplasmosis with ketoconazole. Ann Intern Med 1985;103:861-872.
47. Dorsey JK, Hardy BG, Walker SE. An evaluation of the dose-dependent pharmacokinetics of ketoconazole. Clin Pharmacol Ther 1988;43:188.
48. Lopez-Gil JA. Fluconazole-Cyclosporine Interaction: a dose-dependent effect? Annals Pharmacotherapy 1993;27:427-430.
49. Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother 1990;34:2032-2033.
50. 14C] fluconazole in humans. Drug Metab Dispos 1991;19:764-767.
51. Kunzendorf U, Brockmooler J, Jochimsen F, Roots I, Offerman G. Activity of cyclosporin metabolites M17 and M1. Transplant Proc 1990;22:1697-1699.
52. Fahr A, Hiestand P, Ryffel B. Studies on the biologic activities of Sandimmun metabolites in humans and in animal models: review and original experiments. Transplant Proc 1990;22:1116-1124.
53. Sewing K-Fr, Christians U, Kohlhaw K, et al. Biologic activity of cyclosporine metabolites. Transplant Proc 1990;22:1129-1134.
54. Kim PCW, Cohen Z, Wong PY, Craig M, Cullen J, Levy GA. Cyclosporine A vs cyclosporine A metabolites: comparison of in vivo and in vitro. Transplant Proc 1990;22:2487-2490.
55. Whiting PH. Prospects for the development of immunosuppressive drugs with reduced nephrotoxicity. Exp Opin Invest Drugs 1996;5:43-48.